Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes

American Journal of Pathology

Volumn 173, Issue 6, 2008, Pages 1861-1872

  Farassati, Faris ^a,e   Pan, Weihong ^a   Yamoutpour, Farnaz ^a   Henke, Susann ^b   Piedra, Mark ^c   Frahm, Silke ^b   Al Tawil, Said ^a   Mangrum, Wells I ^c   Parada, Luis F ^d   Rabkin, Samuel D ^b   Martuza, Robert L ^b   Kurtz, Andreas ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; ONCOLYTIC HERPES VIRUS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; VIRUS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; GENOTYPE; HERPES; HERPES SIMPLEX VIRUS 1; MOUSE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCHWANN CELL; SIMIAN VIRUS 40; VIRUS MUTATION;

EID: 57149092129     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2008.080376     Document Type: Article

References (75)

1. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22
2. Cox AD, Der CJ: Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002, 1:599-606
3. Campbell PM, Der CJ: Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004, 14:105-114
4. Bollag G, Freeman S, Lyons JF, Post LE: Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003, 4:1436-1441
5. Jones HA, Hahn SM, Bernhard E, McKenna WG: Ras inhibitors and radiation therapy. Semin Radiat Oncol 2001, 11:328-337
6. Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, Sartor CI, Der CJ: Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004, 64:4585-4592
7. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat 2000, 62:51-62
8. Kurebayashi J: Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001, 8:45-51
9. Li T, Sparano JA: Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 2003, 3:405-420
10. Shackney SE, Silverman JF: Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 2003, 10:278-290
11. Bakin RE, Gioeli D, Bissonette EA, Weber MJ: Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003, 63:1975-1980
12. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003, 63:1981-1989
13. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284
14. Maroni PD, Koul S, Meacham RB, Koul HK: Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Commun Signal 2004, 2:5
15. Nemoto K, Vogt A, Oguri T, Lazo JS: Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate 2004, 58:95-102
16. Weber MJ, Gioeli D: Ras signaling in prostate cancer progression. J Cell Biochem 2004, 91:13-25
17. Moyret-Lalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C: Ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995, 64:124-129
18. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD: Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest 1993, 11:25-32
19. Firgaira FA, Seshadri R, McEvoy CR, Dite GS, Giles GG, McCredie MR, Southey MC, Venter DJ, Hopper JL: HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J Natl Cancer Inst 1999, 91:2107-2111
20. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ: Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001, 7:1214-1220
21. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715
22. Cichowski K, Jacks T: NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604
23. Lynch TM, Gutmann DH: Neurofibromatosis 1. Neurol Clin 2002, 20:841-865
24. Frahm S, Kurtz A, Kluwe L, Farassati F, Friedrich RE, Mautner VF: Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. Cancer Cell Int 2004, 4:4
25. Woodruff JM: Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 1999, 89:23-30
26. Harrisingh MC, Lloyd AC: Ras/Raf/ERK signalling and NF1. Cell Cycle 2004, 3:1255-1258
27. Der SD, Yang YL, Weissmann C, Williams BR: A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 1997, 94:3279-3283
28. Rasmussen SA, Friedman JM: NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33-40
29. Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH: Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 2001, 33:314-323
30. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N: Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000, 275:30740-30745
31. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, Estivill X, Lazaro C: Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997, 61:512-519
32. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990, 87:5435-5439
33. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosom Cancer 1994, 10:250-255
34. Rey JA, Pestana A, Bello MJ: Cytogenetics and molecular genetics of nervous system tumors. Oncol Res 1992, 4:321-331
35. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF: Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179
36. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T: Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176
37. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995, 1:938-943
38. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant. G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000, 7:867-874
39. Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A: Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol 2001, 169:64-71
40. Farassati F, Lee PW: Ras signalling pathway: a gateway for HSV-1 infection. Sci World J 2003, 3:533-535
41. Farassati F, Yang AD, Lee PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001, 3:745-750
42. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334
43. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW: Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002, 13:641-652
44. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998, 17:3351-3362
45. Kyosseva SV: Mitogen-activated protein kinase signaling. Int Rev Neurobiol 2004, 59:201-220
46. Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177-182
47. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532
48. Rodriguez-Viciana P, Downward J: Ras activation of phosphatidylinositol 3-kinase and Akt. Methods Enzymol 2001, 333:37-44
49. Al-Mohanna MA, Al-Khodairy FM, Krezolek Z, Bertilsson PA, Al-Houssein KA, Aboussekhra A: p53 is dispensable for UV-induced cell cycle arrest at late G(1) in mammalian cells. Carcinogenesis 2001, 22:573-578
50. Kumlin T, Heikkinen P, Kosma VM, Alhonen L, Janne J, Juutilainen J: p53-independent apoptosis in UV-irradiated mouse skin: possible inhibition by 50 Hz magnetic fields. Radiat Environ Biophys 2002, 41:155-158
51. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG: Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994, 8:1019-1029
52. Park KS, Kim JA, Chai KJ: Molecular assembly of mitogen-activated protein kinase module in ras-transformed NIH3T3 cell line. Exp Mol Med 2000, 32:120-126
53. Jha PK, Beral V, Peto J, Hack S, Hermon C, Deacon J, Mant D, Chilvers C, Vessey MP, Pike MC: Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993, 341:1116-1118
54. Raptis L, Brownell HL, Corbley MJ, Wood KW, Wang D, Haliotis T: Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40. Cell Growth Differ 1997, 8:891-901
55. Grammatikakis N, Jaronczyk K, Siganou A, Vultur A, Brownell HL, Benzaquen M, Rausch C, Lapointe R, Gjoerup O, Roberts TM, Raptis L: Simian virus 40 large tumor antigen modulates the Raf signaling pathway. J Biol Chem 2001, 276:27840-27845
56. Brunet A, Pouyssegur J: Mammalian MAP kinase modules: how to transduce specific signals. Essays Biochem 1997, 32:1-16
57. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ: Increasing complexity of Ras signaling. Oncogene 1998, 17:1395-1413
58. Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79:143-180
59. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994, 369:156-160
60. Martín-Blanco E: p38 MAPK signalling cascades: ancient roles and new functions. Bioessays 2000, 22:637-645
61. Paul A, Wilson S, Belham CM, Robinson CJ, Scott PH, Gould GW, Plevin R: Stress-activated protein kinases: activation, regulation and function. Cell Signal 1997, 9:403-410
62. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ, Stanbridge EJ: Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999, 18:1807-1817
63. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J: Phosphatidylinositol 3 kinase: one of the effectors of Ras. Philos Trans R Soc Lond B Biol Sci 1996, 351:222-231
64. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321
65. Feldkamp MM, Angelov L, Guha A: Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999, 51:211-218
66. McCormick F: Ras signaling and NF1. Curr Opin Genet Dev 1995, 5:51-55
67. Norman KL, Farassati F, Lee PW: Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 2001, 12:271-282
68. Wildner O: Oncolytic viruses as therapeutic agents. Ann Med 2001, 33:291-304
69. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997, 57:1502-1509
70. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL: Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector g207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001, 3:451-456
71. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999, 73:6319-6326
72. Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL: Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001, 12:999-1010
73. Shmulevitz M, Marcato P, Lee PW: Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005, 24:7720-7728
74. Kalbacova M, Spisakova M, Liskova J, Melkova Z: Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Virus Res 2008, 135:53-63
75. Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP: Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007, 15:279-286